End of season influenza vaccine effectiveness in adults and children in the United Kingdom in 2017/18
BackgroundIn the United Kingdom (UK), in recent influenza seasons, children are offered a quadrivalent live attenuated influenza vaccine (LAIV4), and eligible adults mainly trivalent inactivated vaccine (TIV).AimTo estimate the UK end-of-season 2017/18 adjusted vaccine effectiveness (aVE) and the se...
| Hlavní autoři: | , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Médium: | Journal article |
| Jazyk: | English |
| Vydáno: |
European Centre for Disease Prevention and Control
2019
|
| _version_ | 1826276498564186112 |
|---|---|
| author | Pebody, R Djennad, A Ellis, J Andrews, N Marques, D Cottrell, S Reynolds, A Gunson, R Galiano, M Hoschler, K Lackenby, A Robertson, C O'Doherty, M Sinnathamby, M Panagiotopoulos, N Yonova, I Webb, R Moore, C Donati, M Sartaj, M Shepherd, S McMenamin, J de Lusignan, S Zambon, M |
| author_facet | Pebody, R Djennad, A Ellis, J Andrews, N Marques, D Cottrell, S Reynolds, A Gunson, R Galiano, M Hoschler, K Lackenby, A Robertson, C O'Doherty, M Sinnathamby, M Panagiotopoulos, N Yonova, I Webb, R Moore, C Donati, M Sartaj, M Shepherd, S McMenamin, J de Lusignan, S Zambon, M |
| author_sort | Pebody, R |
| collection | OXFORD |
| description | BackgroundIn the United Kingdom (UK), in recent influenza seasons, children are offered a quadrivalent live attenuated influenza vaccine (LAIV4), and eligible adults mainly trivalent inactivated vaccine (TIV).AimTo estimate the UK end-of-season 2017/18 adjusted vaccine effectiveness (aVE) and the seroprevalence in England of antibodies against influenza viruses cultured in eggs or tissue.MethodsThis observational study employed the test-negative case-control approach to estimate aVE in primary care. The population-based seroprevalence survey used residual age-stratified samples.ResultsInfluenza viruses A(H3N2) (particularly subgroup 3C.2a2) and B (mainly B/Yamagata/16/88-lineage, similar to the quadrivalent vaccine B-virus component but mismatched to TIV) dominated. All-age aVE was 15% (95% confidence interval (CI): -6.3 to 32) against all influenza; -16.4% (95% CI: -59.3 to 14.9) against A(H3N2); 24.7% (95% CI: 1.1 to 42.7) against B and 66.3% (95% CI: 33.4 to 82.9) against A(H1N1)pdm09. For 2-17 year olds, LAIV4 aVE was 26.9% (95% CI: -32.6 to 59.7) against all influenza; -75.5% (95% CI: -289.6 to 21) against A(H3N2); 60.8% (95% CI: 8.2 to 83.3) against B and 90.3% (95% CI: 16.4 to 98.9) against A(H1N1)pdm09. For ≥ 18 year olds, TIV aVE against influenza B was 1.9% (95% CI: -63.6 to 41.2). The 2017 seroprevalence of antibody recognising tissue-grown A(H3N2) virus was significantly lower than that recognising egg-grown virus in all groups except 15-24 year olds.ConclusionsOverall aVE was low driven by no effectiveness against A(H3N2) possibly related to vaccine virus egg-adaption and a new A(H3N2) subgroup emergence. The TIV was not effective against influenza B. LAIV4 against influenza B and A(H1N1)pdm09 was effective. |
| first_indexed | 2024-03-06T23:14:52Z |
| format | Journal article |
| id | oxford-uuid:66c863a0-1c34-4c69-81ec-6d4b4f4f6ec1 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T23:14:52Z |
| publishDate | 2019 |
| publisher | European Centre for Disease Prevention and Control |
| record_format | dspace |
| spelling | oxford-uuid:66c863a0-1c34-4c69-81ec-6d4b4f4f6ec12022-03-26T18:34:05ZEnd of season influenza vaccine effectiveness in adults and children in the United Kingdom in 2017/18Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:66c863a0-1c34-4c69-81ec-6d4b4f4f6ec1EnglishSymplectic Elements at OxfordEuropean Centre for Disease Prevention and Control2019Pebody, RDjennad, AEllis, JAndrews, NMarques, DCottrell, SReynolds, AGunson, RGaliano, MHoschler, KLackenby, ARobertson, CO'Doherty, MSinnathamby, MPanagiotopoulos, NYonova, IWebb, RMoore, CDonati, MSartaj, MShepherd, SMcMenamin, Jde Lusignan, SZambon, MBackgroundIn the United Kingdom (UK), in recent influenza seasons, children are offered a quadrivalent live attenuated influenza vaccine (LAIV4), and eligible adults mainly trivalent inactivated vaccine (TIV).AimTo estimate the UK end-of-season 2017/18 adjusted vaccine effectiveness (aVE) and the seroprevalence in England of antibodies against influenza viruses cultured in eggs or tissue.MethodsThis observational study employed the test-negative case-control approach to estimate aVE in primary care. The population-based seroprevalence survey used residual age-stratified samples.ResultsInfluenza viruses A(H3N2) (particularly subgroup 3C.2a2) and B (mainly B/Yamagata/16/88-lineage, similar to the quadrivalent vaccine B-virus component but mismatched to TIV) dominated. All-age aVE was 15% (95% confidence interval (CI): -6.3 to 32) against all influenza; -16.4% (95% CI: -59.3 to 14.9) against A(H3N2); 24.7% (95% CI: 1.1 to 42.7) against B and 66.3% (95% CI: 33.4 to 82.9) against A(H1N1)pdm09. For 2-17 year olds, LAIV4 aVE was 26.9% (95% CI: -32.6 to 59.7) against all influenza; -75.5% (95% CI: -289.6 to 21) against A(H3N2); 60.8% (95% CI: 8.2 to 83.3) against B and 90.3% (95% CI: 16.4 to 98.9) against A(H1N1)pdm09. For ≥ 18 year olds, TIV aVE against influenza B was 1.9% (95% CI: -63.6 to 41.2). The 2017 seroprevalence of antibody recognising tissue-grown A(H3N2) virus was significantly lower than that recognising egg-grown virus in all groups except 15-24 year olds.ConclusionsOverall aVE was low driven by no effectiveness against A(H3N2) possibly related to vaccine virus egg-adaption and a new A(H3N2) subgroup emergence. The TIV was not effective against influenza B. LAIV4 against influenza B and A(H1N1)pdm09 was effective. |
| spellingShingle | Pebody, R Djennad, A Ellis, J Andrews, N Marques, D Cottrell, S Reynolds, A Gunson, R Galiano, M Hoschler, K Lackenby, A Robertson, C O'Doherty, M Sinnathamby, M Panagiotopoulos, N Yonova, I Webb, R Moore, C Donati, M Sartaj, M Shepherd, S McMenamin, J de Lusignan, S Zambon, M End of season influenza vaccine effectiveness in adults and children in the United Kingdom in 2017/18 |
| title | End of season influenza vaccine effectiveness in adults and children in the United Kingdom in 2017/18 |
| title_full | End of season influenza vaccine effectiveness in adults and children in the United Kingdom in 2017/18 |
| title_fullStr | End of season influenza vaccine effectiveness in adults and children in the United Kingdom in 2017/18 |
| title_full_unstemmed | End of season influenza vaccine effectiveness in adults and children in the United Kingdom in 2017/18 |
| title_short | End of season influenza vaccine effectiveness in adults and children in the United Kingdom in 2017/18 |
| title_sort | end of season influenza vaccine effectiveness in adults and children in the united kingdom in 2017 18 |
| work_keys_str_mv | AT pebodyr endofseasoninfluenzavaccineeffectivenessinadultsandchildrenintheunitedkingdomin201718 AT djennada endofseasoninfluenzavaccineeffectivenessinadultsandchildrenintheunitedkingdomin201718 AT ellisj endofseasoninfluenzavaccineeffectivenessinadultsandchildrenintheunitedkingdomin201718 AT andrewsn endofseasoninfluenzavaccineeffectivenessinadultsandchildrenintheunitedkingdomin201718 AT marquesd endofseasoninfluenzavaccineeffectivenessinadultsandchildrenintheunitedkingdomin201718 AT cottrells endofseasoninfluenzavaccineeffectivenessinadultsandchildrenintheunitedkingdomin201718 AT reynoldsa endofseasoninfluenzavaccineeffectivenessinadultsandchildrenintheunitedkingdomin201718 AT gunsonr endofseasoninfluenzavaccineeffectivenessinadultsandchildrenintheunitedkingdomin201718 AT galianom endofseasoninfluenzavaccineeffectivenessinadultsandchildrenintheunitedkingdomin201718 AT hoschlerk endofseasoninfluenzavaccineeffectivenessinadultsandchildrenintheunitedkingdomin201718 AT lackenbya endofseasoninfluenzavaccineeffectivenessinadultsandchildrenintheunitedkingdomin201718 AT robertsonc endofseasoninfluenzavaccineeffectivenessinadultsandchildrenintheunitedkingdomin201718 AT odohertym endofseasoninfluenzavaccineeffectivenessinadultsandchildrenintheunitedkingdomin201718 AT sinnathambym endofseasoninfluenzavaccineeffectivenessinadultsandchildrenintheunitedkingdomin201718 AT panagiotopoulosn endofseasoninfluenzavaccineeffectivenessinadultsandchildrenintheunitedkingdomin201718 AT yonovai endofseasoninfluenzavaccineeffectivenessinadultsandchildrenintheunitedkingdomin201718 AT webbr endofseasoninfluenzavaccineeffectivenessinadultsandchildrenintheunitedkingdomin201718 AT moorec endofseasoninfluenzavaccineeffectivenessinadultsandchildrenintheunitedkingdomin201718 AT donatim endofseasoninfluenzavaccineeffectivenessinadultsandchildrenintheunitedkingdomin201718 AT sartajm endofseasoninfluenzavaccineeffectivenessinadultsandchildrenintheunitedkingdomin201718 AT shepherds endofseasoninfluenzavaccineeffectivenessinadultsandchildrenintheunitedkingdomin201718 AT mcmenaminj endofseasoninfluenzavaccineeffectivenessinadultsandchildrenintheunitedkingdomin201718 AT delusignans endofseasoninfluenzavaccineeffectivenessinadultsandchildrenintheunitedkingdomin201718 AT zambonm endofseasoninfluenzavaccineeffectivenessinadultsandchildrenintheunitedkingdomin201718 |